Teodoro J. Oscanoa*, José Amado, Xavier Vidal and Roman Romero-Ortuno Pages 1-6 (6)
Methods: We systematically searched studies reporting the association between ARB use and incidence of AD.
Results: Ten studies (1 RCT, 2 case-control studies and 7 cohort studies) met the inclusion criteria. When all observational studies (9) were analyzed, ARB use was associated with a reduced risk of incident AD (HR 0.72, 95% CI: 0.58-0.88, p<0.001). In the only RCT, the decrease in the incidence of AD was also significant (HR= 0.31,95% CI:0.14-0.68).
Conclusion: ARB use may reduce the risk of incident AD. This association does not imply causation and further research is required to clarify potential mechanisms.
Angiotensin-Receptor Blockers, Alzheimer's Disease, elderly, Angiotensin II, meta-analysis
Centro de Investigación de Seguridad de Medicamentos de la Facultad de Medicina Humana de la Universidad de San Martín de Porres (FMH-USMP),Lima, Centro de Investigación de Seguridad de Medicamentos de la Facultad de Medicina Humana de la Universidad de San Martín de Porres (FMH-USMP),Lima, Clinical Pharmacology Department, Valld’Hebrón Hospital, Barcelona, Trinity College Dublin, Discipline of Medical Gerontology, Mercer’s Institute for Successful Ageing, St James’s Hospital, Dublin